afegostat

Afegostat is a pharmacological chaperone that specifically and reversibly binds acid-β-glucosidase (GCase) in the endoplasmic reticulum with high affinity.

Afegostat D-Tartrate is a pharmacological chaperone that binds specifically and reversibly with high affinity to acid-β-glucosidase (GCase) in the endoplasmic reticulum.

Afegostat, aslo known as Isofagomine, and AT2101, was an experimental drug for the treatment of certain forms of Gaucher's disease. Isofagomine (IFG) is an acid β-glucosidase (GCase) active site inhibitor that acts as a pharmacological chaperone. FG inhibits GCase with K(i) ~30 nM for wild-type and mutant enzymes (N370S and V394L). Administration of IFG (30 mg/kg/day) to the mice homozygous for GCase mutations (V394L, D409H, or D409V) led to increased GCase activity in visceral tissues and brain extracts.

L-Afegostat (5-epi-Isofagomine), a glycosidase inhibitor and an iminosugar, is utilized in carbohydrate synthesis. It demonstrates β-Glucosidase inhibition with a Ki of 30 μM.

Afegostat is an acid β-glucosidase (GCase) active site inhibitor that acts as a pharmacological chaperone. Afegostat inhibits GCase with K(i) ~30 nM for wild-type and mutant enzymes. Afegostat was an experimental drug for the treatment of certain forms of

H-201-70 is a partial beta1 agonist with adrenoreceptor stimulatory effects.